enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Anti-amyloid drugs - Wikipedia

    en.wikipedia.org/wiki/Anti-amyloid_drugs

    Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...

  3. Who is eligible for the new FDA-approved Alzheimer's drug? - AOL

    www.aol.com/lifestyle/explainer-eligible-fda...

    Because it is a disease of aging, most Alzheimer's patients are covered by Medicare, which had effectively denied coverage of Leqembi under the accelerated approval it received in January. The ...

  4. New test may tell who is prone to side effects from Alzheimer ...

    www.aol.com/test-may-tell-prone-side-153000197.html

    The Food and Drug Administration (FDA) approved lecanemab, sold under the brand name Leqembi — the first anti-amyloid medication for the treatment of Alzheimer’s disease.

  5. U.S. approves Alzheimer's drug that modestly slows disease - AOL

    www.aol.com/news/alzheimers-drug-modestly-slows...

    A string of other amyloid-targeting drugs have failed and many researchers now think combination treatments will be needed. Aduhelm, the similar drug, was marred by controversy over its effectiveness.

  6. Aducanumab - Wikipedia

    en.wikipedia.org/wiki/Aducanumab

    Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.

  7. Solanezumab - Wikipedia

    en.wikipedia.org/wiki/Solanezumab

    Solanezumab binds the amyloid-β peptides that aggregate and form plaques in the brain that are an early pathological feature of Alzheimer's disease. [11] Solanezumab binds the central epitope of monomeric amyloid-β, KLVFFAED, (PDB ID 4XXD [12]) with picomolar affinity. [13]

  8. Promising new Alzheimer's drugs may benefit whites more than ...

    www.aol.com/news/promising-alzheimers-drugs-may...

    Groundbreaking treatments for Alzheimer's disease that work by removing a toxic protein called beta amyloid from the brain may benefit whites more than Black Americans, whose disease may be driven ...

  9. Lecanemab - Wikipedia

    en.wikipedia.org/wiki/Lecanemab

    Lecanemab may cause amyloid-related imaging abnormalities (ARIA). ARIA is often asymptomatic, but serious and life-threatening events rarely may occur.ARIA most commonly presents as temporary swelling of the brain that usually resolves over time and may be accompanied by small spots of bleeding in or on the surface of the brain, though some people may have symptoms such as headache, confusion ...